Vir Advances Antibodies Against COVID-19, CEO Scangos Leads BIO’s Coronavirus Outreach
Scrip talked to George Scangos about his dual roles in the pandemic response, helming Vir as the company tests antibody and siRNA approaches while working with BIO to facilitate coronavirus collaborations.
You may also be interested in...
Vir’s George Scangos, Westlake Village BioPartners’ Sean Harper, Kronos Bio’s Norbert Bischofberger, Scorpion’s Axel Hoos and Eikon’s Roy Baynes discuss the experiences they bring and the challenges they have faced in the transition from large drug makers to small biotechs.
Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.
Results from a Phase II/III study for VIR-7831 in the prevention of hospitalization due to COVID-19 are expected in late 2020 and early 2021.